<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Saudi J Anaesth</journal-id><journal-id journal-id-type="iso-abbrev">Saudi J Anaesth</journal-id><journal-id journal-id-type="publisher-id">SJA</journal-id><journal-title-group><journal-title>Saudi Journal of Anaesthesia</journal-title></journal-title-group><issn pub-type="ppub">1658-354X</issn><issn pub-type="epub">0975-3125</issn><publisher><publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25829902</article-id><article-id pub-id-type="pmc">4374219</article-id><article-id pub-id-type="publisher-id">SJA-9-148</article-id><article-id pub-id-type="doi">10.4103/1658-354X.152841</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Dexmedetomidine as an adjuvant to ropivacaine in supraclavicular brachial plexus block</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kathuria</surname><given-names>Suneet</given-names></name><xref ref-type="aff" rid="aff1"></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Shikha</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Dhawan</surname><given-names>Ira</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib></contrib-group><aff id="aff1"><italic>Department of Anesthesia. Dayanand Medical College and Hospital, Ludhiana, Punjab, India</italic></aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Suneet Kathuria, Department of Anesthesia, Dayanand Medical College and Hospital, Ludhiana - 141 001, Punjab, India. E-mail: <email xlink:href="suneetkathuria@hotmail.com">suneetkathuria@hotmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Apr-Jun</season><year>2015</year></pub-date><volume>9</volume><issue>2</issue><fpage>148</fpage><lpage>154</lpage><permissions><copyright-statement>Copyright: © Saudi Journal of Anaesthesia</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="2909" xml_f="2917" txt_i="11" txt_f="19">Context:</offsets></title><p><offsets xml_i="2928" xml_f="3043" txt_i="20" txt_f="135">Dexmedetomidine as an adjuvant to local anesthetics in peripheral nerve blocks has been used in only a few studies.</offsets></p></sec><sec id="st2"><title><offsets xml_i="3074" xml_f="3079" txt_i="137" txt_f="142">Aims:</offsets></title><p><offsets xml_i="3090" xml_f="3213" txt_i="143" txt_f="266">We aimed at assessing the effect of dexmedetomidine as an adjuvant to ropivacaine in supraclavicular brachial plexus block.</offsets></p></sec><sec id="st3"><title><offsets xml_i="3244" xml_f="3264" txt_i="268" txt_f="288">Settings and Design:</offsets></title><p><offsets xml_i="3275" xml_f="3312" txt_i="289" txt_f="326">Random, controlled, and triple blind.</offsets></p></sec><sec id="st4"><title><offsets xml_i="3343" xml_f="3365" txt_i="328" txt_f="350">Materials and Methods:</offsets></title><p><offsets xml_i="3376" xml_f="3882" txt_i="351" txt_f="857">Sixty American Society of Anesthesiologist grade I and II patients of either sex scheduled for elective upper limb surgery under supraclavicular brachial plexus block were divided into three equal groups in a prospective randomized double-blind controlled manner. For block patients in Group C received 0.5% ropivacaine (30cc), 0.5% ropivacaine with 50 μg dexmedetomidine (30cc) in Group D and 0.5% ropivacaine (30cc) in Group D-IV along with intravenous infusion of 50 μg dexmedetomidine in normal saline.</offsets></p></sec><sec id="st5"><title><offsets xml_i="3913" xml_f="3939" txt_i="859" txt_f="885">Statistical Analysis Used:</offsets></title><p><offsets xml_i="3950" xml_f="4017" txt_i="886" txt_f="953">IBM-SPSS software version 17, Chi-square test, Mann-Whitney U-test.</offsets></p></sec><sec id="st6"><title><offsets xml_i="4048" xml_f="4056" txt_i="955" txt_f="963">Results:</offsets></title><p><offsets xml_i="4067" xml_f="4457" txt_i="964" txt_f="1354">Demographic profile and surgical characteristics were similar in all the three groups. Sensory block and motor block onset was earlier in group D than in group D-IV and group C. The sensory block and motor block duration was also prolonged in group D when compared with group D-IV and group C. The duration of analgesia was significantly longer in group D and D-IV when compared to group C.</offsets></p></sec><sec id="st7"><title><offsets xml_i="4488" xml_f="4500" txt_i="1356" txt_f="1368">Conclusions:</offsets></title><p><offsets xml_i="4511" xml_f="4832" txt_i="1369" txt_f="1690">Dexmedetomidine as an adjuvant to 0.5%ropivacaine in ultrasound guided brachial plexus block shortens the sensory as well as motor block onset time, prolongs sensory and motor block duration and also increases the duration of analgesia. The action of dexmedetomidine most probably is local rather than centrally mediated.</offsets></p></sec></abstract><kwd-group><kwd><italic>Dexmedetomidine</italic></kwd><kwd><italic>ropivacaine</italic></kwd><kwd><italic>supraclavicular brachial plexus block</italic></kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title><offsets xml_i="5093" xml_f="5105" txt_i="1699" txt_f="1711">INTRODUCTION</offsets></title><p><offsets xml_i="5116" xml_f="5658" txt_i="1712" txt_f="2254">Brachial plexus block has evolved as an important tool in the anesthesiologist's armamentarium as a safe alternative to general anesthesia for upper limb surgery and for relief of perioperative pain. Its increased popularity is because of advancements in regional anesthesia techniques in terms of local anesthetic drugs, newer adjuvant drugs and use of ultrasound for safe and successful conduct of block. It helps in reduced hospital stay, less financial burden and also leads to avoidance of undesirable side-effects of general anesthesia.</offsets></p><p><offsets xml_i="5665" xml_f="5929" txt_i="2255" txt_f="2519">Since the introduction of first brachial plexus block using cocaine by Halstead (1884) the technique of brachial plexus block has evolved from classical blind technique to use of nerve stimulators and ultrasound guidance for supraclavicular brachial plexus block.[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="5962" xml_f="5963" txt_i="2519" txt_f="2520">1</offsets></xref><offsets xml_i="5970" xml_f="6161" txt_i="2520" txt_f="2711">] Many additives to local anesthetics such as opioids, clonidine, neostigmine and tramadol etc. have been used to increase the duration of the block, to improve postoperative pain management[</offsets><xref rid="ref2" ref-type="bibr"><offsets xml_i="6194" xml_f="6195" txt_i="2711" txt_f="2712">2</offsets></xref><offsets xml_i="6202" xml_f="6319" txt_i="2712" txt_f="2829">] and to avoid the need for placing catheter for continuous local anesthetic drug infusion. Dexmedetomidine a newer α</offsets><sub><offsets xml_i="6324" xml_f="6325" txt_i="2829" txt_f="2830">2</offsets></sub><offsets xml_i="6331" xml_f="6606" txt_i="2830" txt_f="3105">-adrenoreceptor agonist is currently in focus for its sedative, anxiolytic and analgesic properties. Pre- and intra-operative intravenous dexmedetomidine administration has shown to prolong the duration of sensory block with local anesthetics during peripheral nerve blocks.[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="6639" xml_f="6640" txt_i="3105" txt_f="3106">3</offsets></xref><offsets xml_i="6647" xml_f="6648" txt_i="3106" txt_f="3107">]</offsets></p><p><offsets xml_i="6655" xml_f="6791" txt_i="3108" txt_f="3244">Animal studies have shown that dexmedetomidine enhances onset of sensory and motor blockade along with increased duration of analgesia.[</offsets><xref rid="ref4" ref-type="bibr"><offsets xml_i="6824" xml_f="6825" txt_i="3244" txt_f="3245">4</offsets></xref><xref rid="ref5" ref-type="bibr"><offsets xml_i="6865" xml_f="6866" txt_i="3245" txt_f="3246">5</offsets></xref><offsets xml_i="6873" xml_f="7043" txt_i="3246" txt_f="3416">] In human beings, dexmedetomidine has also shown to prolong the duration of block and postoperative analgesia when added to local anesthetic in various regional blocks.[</offsets><xref rid="ref6" ref-type="bibr"><offsets xml_i="7076" xml_f="7077" txt_i="3416" txt_f="3417">6</offsets></xref><xref rid="ref7" ref-type="bibr"><offsets xml_i="7117" xml_f="7118" txt_i="3417" txt_f="3418">7</offsets></xref><xref rid="ref8" ref-type="bibr"><offsets xml_i="7158" xml_f="7159" txt_i="3418" txt_f="3419">8</offsets></xref><offsets xml_i="7166" xml_f="7301" txt_i="3419" txt_f="3554">] Most human studies of dexmedetomidine as an adjuvant to local anesthetics involved combinations with bupivacaine or levobupivacaine.[</offsets><xref rid="ref9" ref-type="bibr"><offsets xml_i="7334" xml_f="7335" txt_i="3554" txt_f="3555">9</offsets></xref><xref rid="ref10" ref-type="bibr"><offsets xml_i="7376" xml_f="7378" txt_i="3555" txt_f="3557">10</offsets></xref><offsets xml_i="7385" xml_f="7653" txt_i="3557" txt_f="3825">] Due to unique pharmacologic properties and fewer side effects, ropivacaine is being preferred by an increasing number of anesthesiologists for peripheral nerve blocks. However, there are very few published studies on dexmedetomidine in combination with ropivacaine.[</offsets><xref rid="ref6" ref-type="bibr"><offsets xml_i="7686" xml_f="7687" txt_i="3825" txt_f="3826">6</offsets></xref><xref rid="ref11" ref-type="bibr"><offsets xml_i="7728" xml_f="7730" txt_i="3826" txt_f="3828">11</offsets></xref><offsets xml_i="7737" xml_f="8132" txt_i="3828" txt_f="4223">] The current study was designed with aim to evaluate the effect of adding dexmedetomidine to ropivacaine 0.5% in supraclavicular brachial plexus block in terms of onset and duration of sensory and motor block, quality of block, duration of postoperative analgesia and to test the hypothesis whether the effect of dexmedetomidine, is due to local action on nerve plexus or is centrally mediated.</offsets></p></sec><sec sec-type="materials|methods" id="sec1-2"><title><offsets xml_i="8195" xml_f="8216" txt_i="4225" txt_f="4246">MATERIALS AND METHODS</offsets></title><p><offsets xml_i="8227" xml_f="8802" txt_i="4247" txt_f="4822">After ethical committee approval and written informed consent, 60 American Society of Anesthesiologist (ASA) grade I or II patients, scheduled for elective upper limb surgery below mid-humerus level under supraclavicular brachial plexus block were enrolled in this prospective, randomized, double-blind controlled trial. Preanesthetic assessment of all the patients was done the day before scheduled surgery. Patients were premedicated with tablet alprazolam 0.25 mg and tablet ranitidine 150 mg on night before surgery and also in the morning of surgery with a sip of water.</offsets></p><p><offsets xml_i="8809" xml_f="9155" txt_i="4823" txt_f="5169">Patients with preexisting peripheral neuropathy of upper limb, bleeding disorders, infection at injection site, untreated pneumothorax, patients on adrenoreceptor agonist or antagonist therapy, history of severe cardiac, respiratory, hepatic or renal disease, pregnancy and known hypersensitivity to the study drugs, were excluded from the study.</offsets></p><p><offsets xml_i="9162" xml_f="9270" txt_i="5170" txt_f="5278">Using a computer generated randomization, patients were randomized into three groups of 20 patients each as:</offsets></p><p><offsets xml_i="9277" xml_f="9475" txt_i="5279" txt_f="5477">Group C: Ultrasound-guided supraclavicular brachial plexus block given with 30 ml Ropivacaine 0.5% (study drug [I]) and 50 ml normal saline (study drug [II]) administered as IV infusion over 15 min.</offsets></p><p><offsets xml_i="9482" xml_f="9720" txt_i="5478" txt_f="5716">Group D: Ultrasound-guided supraclavicular brachial plexus block given with 30 ml Ropivacaine 0.5% containing 50 μg dexmedetomidine (study drug [I]) and 50 ml normal saline (0.9%) (study drug [II]) administered as IV infusion over 15 min.</offsets></p><p><offsets xml_i="9727" xml_f="9961" txt_i="5717" txt_f="5951">Group D-IV: Ultrasound-guided supraclavicular brachial plexus block given with 30 ml Ropivacaine 0.5% (study drug [I]) and 50 ml normal saline containing 50 μg dexmedetomidine (study drug [II]) administered as IV infusion over 15 min.</offsets></p><p><offsets xml_i="9968" xml_f="10127" txt_i="5952" txt_f="6111">Coded study drug solutions were prepared by an anesthesiologist not involved in further study and handed over to concerned anesthesiologist for administration.</offsets></p><p><offsets xml_i="10134" xml_f="10341" txt_i="6112" txt_f="6319">After shifting the patient to operating table, standard anesthesia monitoring in the form of the baseline measurement of heart rate, noninvasive arterial blood pressure, and peripheral oxygen saturation (SpO</offsets><sub><offsets xml_i="10346" xml_f="10347" txt_i="6319" txt_f="6320">2</offsets></sub><offsets xml_i="10353" xml_f="10443" txt_i="6320" txt_f="6410">) was started. Intravenous access was achieved using 20 G cannula in the nonoperative arm.</offsets></p><p><offsets xml_i="10450" xml_f="10984" txt_i="6411" txt_f="6945">After aseptic preparation of the area, surpraclavicular brachial plexus block was performed under ultrasound guidance (Sonosite, Micromaxx machine with high frequency (13 MHz) linear probe) with 30 ml of study drug (I) by an anesthesiologist who was unaware of the nature of study drug solution. The spread of injected drug was observed sonologically in real time to achieve a satisfactory spread of the drug around the brachial plexus. Intravenous infusion of 50 ml study drug (II) was also started at the time of starting the block.</offsets></p><p><offsets xml_i="10991" xml_f="11748" txt_i="6946" txt_f="7703">Sensory and motor block evaluation was done every 3 min after giving block until complete sensory and motor block or 30 min, whichever was earlier. Sensory block was assessed by pinprick test with a blunt 23 G hypodermic needle in the distribution of all four nerves (ulnar, median, radial and musculocutaneous nerves) using a 3-point scale as: 0 = Normal sensation, 1 = Loss of sensation of prick (analgesia), 2 = Loss of sensation of touch (anesthesia). Motor block was evaluated by thumb abduction (radial nerve), thumb adduction (ulnar nerve), thumb opposition (median nerve), and flexion at elbow (musculocutaneous nerve) on a 3-point scale as: 0 = Normal motor function, 1 = Reduced motor strength (but able to move fingers), 2 = Complete motor block.</offsets></p><p><offsets xml_i="11755" xml_f="12111" txt_i="7704" txt_f="8060">Onset time for sensory or motor block was defined as the time interval between the end of total local anesthetic administration and complete sensory or motor block. Complete sensory block was defined by anesthetic block (score 2) on all nerve territories. Complete motor block was defined as the absence of voluntary movement on hand and forearm (score 2).</offsets></p><p><offsets xml_i="12118" xml_f="12443" txt_i="8061" txt_f="8386">At the end of the operation, quality of anesthesia was graded by the anesthesiologist as: Excellent (4): No complaint from the patient, Good (3): Minor complaint with no need for supplemental analgesics, Moderate (2): Complaint that required supplemental analgesics, and Unsuccessful (1): Patient required general anesthesia.</offsets></p><p><offsets xml_i="12450" xml_f="13528" txt_i="8387" txt_f="9465">The observations in the recovery room were made by anesthesiologist who was unaware of the nature of drugs administered. On arrival in recovery room patients were asked to rate their pain on 11 point visual analog scale (VAS) and thereafter pain was assessed regularly every 30 min for first 2 h and then every 1 hourly till 24 h. Testing for sensory and motor block regression was done every 15 min until complete resolution. Duration of sensory block was defined as the time interval between the end of study drug (1) administration and complete resolution of sensation on all nerves. Duration of motor block was defined as the time interval between the end of study drug (1) administration and the recovery of complete motor power of the hand and forearm. Injection diclofenac sodium 75 mg intramuscular was administered when VAS score was ≥4. The time between the end of local anesthetic administration and first rescue analgesic administration was recorded as the duration of analgesia. Total amount of diclofenac sodium used in first 24 h period postoperatively was noted.</offsets></p><p><offsets xml_i="13535" xml_f="13795" txt_i="9466" txt_f="9714">Patients were questioned for nausea, vomiting, skin rash and observed for tachycardia (&gt;20% above baseline value), bradycardia (&lt;50 beats per minute), hypotension (&gt;20% below baseline value), hypertension (&gt;20% above baseline value), hypoxemia (SpO</offsets><sub><offsets xml_i="13800" xml_f="13801" txt_i="9714" txt_f="9715">2</offsets></sub><offsets xml_i="13807" xml_f="14104" txt_i="9715" txt_f="10009"> &lt;90%), sedation or any other side effect if any, during 24 h postoperative period. Sedation was assessed using 5 Point sedation score 1 = Alert and wide awake, 2 = Arousable to verbal command, 3 = Arousable with gentle tactile stimulation, 4 = Arousable with vigorous shaking, 5 = Unarousable.</offsets></p><sec id="sec2-1"><title><offsets xml_i="14132" xml_f="14152" txt_i="10010" txt_f="10030">Statistical analysis</offsets></title><p><offsets xml_i="14163" xml_f="14453" txt_i="10031" txt_f="10321">Data were analyzed using IBM-SPSS software (Produced by SPSS Inc. Released 2008. SPSS Statistics for Windows, Version 17.0. Chicago: SPSS Inc.). Age, height, weight, body mass index (BMI), sensory and motor block onset time, duration of surgery were analyzed by using independent Student's </offsets><italic><offsets xml_i="14461" xml_f="14462" txt_i="10321" txt_f="10322">t</offsets></italic><offsets xml_i="14471" xml_f="14706" txt_i="10322" txt_f="10557">-test. Sex ratio, ASA grade and quality of anesthesia were compared using the Chi-square test. VAS was expressed as median and interquartile range. VAS and sedation score were compared using Mann-Whitney U-test for pairwise comparison.</offsets></p></sec><sec id="sec2-2"><title><offsets xml_i="14740" xml_f="14754" txt_i="10559" txt_f="10573">Power analysis</offsets></title><p><offsets xml_i="14765" xml_f="14767" txt_i="10574" txt_f="10576">A </offsets><italic><offsets xml_i="14775" xml_f="14783" txt_i="10576" txt_f="10584">post-hoc</offsets></italic><offsets xml_i="14792" xml_f="14927" txt_i="10584" txt_f="10719"> power analysis was conducted using the software package; GPower (Faul and Erdfelder 1992). The alpha level used for this analysis was </offsets><italic><offsets xml_i="14935" xml_f="14936" txt_i="10719" txt_f="10720">P</offsets></italic><offsets xml_i="14945" xml_f="14961" txt_i="10720" txt_f="10733"> &lt; 0.05. The </offsets><italic><offsets xml_i="14969" xml_f="14977" txt_i="10733" txt_f="10741">post-hoc</offsets></italic><offsets xml_i="14986" xml_f="15498" txt_i="10741" txt_f="11253"> analyses revealed the statistical power for this study was 0.40 for detecting a small effect, whereas the power exceeded 0.99 for the detection of a moderate to large effect size. Thus, there was more than adequate power (i.e., power ×0.80) at a moderate to large effect size level, but less than adequate statistical power at the small effect size level. A sample size of 60 was used; the statistical power analyses and calculated effect size come out to be 1.91 for analgesic duration and gave the power of 1.</offsets></p></sec></sec><sec sec-type="results" id="sec1-3"><title><offsets xml_i="15557" xml_f="15564" txt_i="11256" txt_f="11263">RESULTS</offsets></title><p><offsets xml_i="15575" xml_f="15783" txt_i="11264" txt_f="11472">There was no statistically significant difference among the patients in the three groups with respect to age, height, weight, BMI, sex ratio, duration of surgery, type of surgery and the ASA physical status [</offsets><xref ref-type="table" rid="T1"><offsets xml_i="15815" xml_f="15822" txt_i="11472" txt_f="11479">Table 1</offsets></xref><offsets xml_i="15829" xml_f="15831" txt_i="11479" txt_f="11481">].</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="15879" xml_f="15886" txt_i="11482" txt_f="11489">Table 1</offsets></label><caption><p><offsets xml_i="15906" xml_f="15922" txt_i="11489" txt_f="11505">Demographic data</offsets></p></caption><graphic xlink:href="SJA-9-148-g001"></graphic></table-wrap><p><offsets xml_i="15999" xml_f="16411" txt_i="11506" txt_f="11918">The sensory and motor block onset was significantly quicker in group D than in group D-IV and group C. The mean sensory block onset time was 9.75 ± 4.23 min in group D as compared to 22.20 ± 8.62 min and 14.55 ± 8.39 min in group C and D-IV, respectively. The mean motor block onset time was 18.75 ± 6.37 min in group D when compared to 39.05 ± 16.38 min and 30.15 ± 14.52 min in group C and D-IV, respectively [</offsets><xref ref-type="table" rid="T2"><offsets xml_i="16443" xml_f="16450" txt_i="11918" txt_f="11925">Table 2</offsets></xref><offsets xml_i="16457" xml_f="16459" txt_i="11925" txt_f="11927">].</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="16507" xml_f="16514" txt_i="11928" txt_f="11935">Table 2</offsets></label><caption><p><offsets xml_i="16534" xml_f="16555" txt_i="11935" txt_f="11956">Block characteristics</offsets></p></caption><graphic xlink:href="SJA-9-148-g002"></graphic></table-wrap><p><offsets xml_i="16632" xml_f="17070" txt_i="11957" txt_f="12395">The duration of sensory as well as motor block was significantly prolonged in group D and group D-IV as compared to group C. The duration of sensory block was maximum in group D (789.45 ± 187.72 min) followed by group D-IV (667.50 ± 121.98 min) and group C (451.60 ± 113.36 min). The duration of motor block was also maximum in group D (754.60 ± 180.50 min), followed by group D-IV (612.00 ± 121.22 min) and group C (387.85 ± 129.31 min).</offsets></p><p><offsets xml_i="17077" xml_f="17312" txt_i="12396" txt_f="12631">The duration of analgesia was significantly prolonged in group D (967.55 ± 310.50 min) and D-IV (970.50 ± 344.90 min) when compared with group C (536.75 ± 251.19 min). The duration of analgesia was comparable between groups D and D-IV.</offsets></p><p><offsets xml_i="17319" xml_f="17548" txt_i="12632" txt_f="12861">The total analgesic consumption in 24 h postoperatively was significantly higher in group C than group D and D-IV. However, the difference in total analgesic consumption between group D and D-IV was not statistically significant.</offsets></p><p><offsets xml_i="17555" xml_f="17845" txt_i="12862" txt_f="13152">No episode of hypoxemia or respiratory depression during 24 h period postoperatively was seen in any patient. Patients in group D and D-IV were more sedated compared to group C. Most of the patients in our study had sedation grade ≤3, except one patient in group D who had grade 4 sedation.</offsets></p><p><offsets xml_i="17852" xml_f="18363" txt_i="13153" txt_f="13664">Bradycardia was observed in one patient belonging to group D-IV intraoperatively that was treated with injection atropine sulfate 0.6 mg IV. Hypotension was observed in two patients each belonging to group D and group D-IV, which was effectively treated with incremental 3 mg IV boluses of injection mephentermine. Skin rash was observed in one patient belonging to group D-IV that was treated with injection pheniramine maleate 45.5 mg IV. No episode of nausea, vomiting, or any other side-effect was observed.</offsets></p></sec><sec sec-type="discussion" id="sec1-4"><title><offsets xml_i="18419" xml_f="18429" txt_i="13666" txt_f="13676">DISCUSSION</offsets></title><p><offsets xml_i="18440" xml_f="18587" txt_i="13677" txt_f="13824">Apart from sedative, analgesic, hemodynamic-stabilizing properties, and sympatholytic pharmacologic effects, the alpha (α)-2-adrenergic receptor (α</offsets><sub><offsets xml_i="18592" xml_f="18593" txt_i="13824" txt_f="13825">2</offsets></sub><offsets xml_i="18599" xml_f="18720" txt_i="13825" txt_f="13946"> -AR) agonists have been used to increase the duration of thermal anti-nociception and analgesia in some animal studies.[</offsets><xref rid="ref4" ref-type="bibr"><offsets xml_i="18753" xml_f="18754" txt_i="13946" txt_f="13947">4</offsets></xref><xref rid="ref5" ref-type="bibr"><offsets xml_i="18794" xml_f="18795" txt_i="13947" txt_f="13948">5</offsets></xref><offsets xml_i="18802" xml_f="19054" txt_i="13948" txt_f="14200">] Animal studies have proven the combination of dexmedetomidine with ropivacaine to be safe and neuro-protective. The use of dexmedetomidine decreases inflammation around peripheral nerves, thereby decreasing the potential for peripheral nerve injury.[</offsets><xref rid="ref12" ref-type="bibr"><offsets xml_i="19088" xml_f="19090" txt_i="14200" txt_f="14202">12</offsets></xref><offsets xml_i="19097" xml_f="19316" txt_i="14202" txt_f="14421">] In human beings, the beneficial effects of adding dexmedetomidine to local anesthetics during regional anesthesia and some peripheral nerve blockade procedures have proved to be efficacious for the surgical patients.[</offsets><xref rid="ref6" ref-type="bibr"><offsets xml_i="19349" xml_f="19350" txt_i="14421" txt_f="14422">6</offsets></xref><xref rid="ref7" ref-type="bibr"><offsets xml_i="19390" xml_f="19391" txt_i="14422" txt_f="14423">7</offsets></xref><xref rid="ref11" ref-type="bibr"><offsets xml_i="19432" xml_f="19434" txt_i="14423" txt_f="14425">11</offsets></xref><offsets xml_i="19441" xml_f="19762" txt_i="14425" txt_f="14746">] To best of our knowledge, this is probably the first human study showing that the addition of dexmedetomidine to ropivacaine in ultrasound-guided supraclavicular brachial plexus block shortens the sensory and motor block onset time, prolongs sensory and motor block duration and also prolongs the duration of analgesia.</offsets></p><p><offsets xml_i="19769" xml_f="19907" txt_i="14747" txt_f="14885">We used 0.5% ropivacaine for supraclavicular block. The rationale for choosing this concentration is supported by the study done by Klein </offsets><italic><offsets xml_i="19915" xml_f="19920" txt_i="14885" txt_f="14890">et al</offsets></italic><offsets xml_i="19929" xml_f="20189" txt_i="14890" txt_f="15150">. in 1998, who found that for interscalene brachial plexus block, increasing the concentration of ropivacaine from 0.5% to 0.75% failed to improve onset or duration of block, suggesting that the risk of increased total dose of local anesthetic may be avoided.[</offsets><xref rid="ref13" ref-type="bibr"><offsets xml_i="20223" xml_f="20225" txt_i="15150" txt_f="15152">13</offsets></xref><offsets xml_i="20232" xml_f="20471" txt_i="15152" txt_f="15391">] Hickey and coworkers have shown that 0.25% ropivacaine when used for subclavian perivascular brachial plexus block for upper limb surgery required frequent analgesia supplementation due to the low concentration of local anesthetic used.[</offsets><xref rid="ref14" ref-type="bibr"><offsets xml_i="20505" xml_f="20507" txt_i="15391" txt_f="15393">14</offsets></xref><offsets xml_i="20514" xml_f="20515" txt_i="15393" txt_f="15394">]</offsets></p><p><offsets xml_i="20522" xml_f="20730" txt_i="15395" txt_f="15603">In our study, we have found that addition of dexmedetomidine (50 μg) to 30 ml ropivacaine 0.5% in ultrasound-guided supraclavicular brachial plexus block resulted in a quick onset of sensory and motor block [</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="20760" xml_f="20768" txt_i="15603" txt_f="15611">Figure 1</offsets></xref><offsets xml_i="20775" xml_f="20830" txt_i="15611" txt_f="15666">], prolonged duration of both sensory and motor block [</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="20860" xml_f="20868" txt_i="15666" txt_f="15674">Figure 2</offsets></xref><offsets xml_i="20875" xml_f="21037" txt_i="15674" txt_f="15836">], delayed time to first request for analgesia supplementation, that is, prolonged duration of analgesia, and significantly decreased 24 h analgesic consumption [</offsets><xref ref-type="fig" rid="F3"><offsets xml_i="21067" xml_f="21075" txt_i="15836" txt_f="15844">Figure 3</offsets></xref><offsets xml_i="21082" xml_f="21183" txt_i="15844" txt_f="15945">] and a good quality of analgesia when compared with control group (ropivacaine 0.5% alone in block).</offsets></p><fig id="F1" position="float"><label><offsets xml_i="21224" xml_f="21232" txt_i="15946" txt_f="15954">Figure 1</offsets></label><caption><p><offsets xml_i="21252" xml_f="21286" txt_i="15954" txt_f="15988">Sensory and motor block onset time</offsets></p></caption><graphic xlink:href="SJA-9-148-g003"></graphic></fig><fig id="F2" position="float"><label><offsets xml_i="21390" xml_f="21398" txt_i="15989" txt_f="15997">Figure 2</offsets></label><caption><p><offsets xml_i="21418" xml_f="21435" txt_i="15997" txt_f="16014">Duration of block</offsets></p></caption><graphic xlink:href="SJA-9-148-g004"></graphic></fig><fig id="F3" position="float"><label><offsets xml_i="21539" xml_f="21547" txt_i="16015" txt_f="16023">Figure 3</offsets></label><caption><p><offsets xml_i="21567" xml_f="21602" txt_i="16023" txt_f="16058">Total analgesic consumption in 24 h</offsets></p></caption><graphic xlink:href="SJA-9-148-g005"></graphic></fig><p><offsets xml_i="21672" xml_f="21681" txt_i="16059" txt_f="16068">Esmaoglu </offsets><italic><offsets xml_i="21689" xml_f="21694" txt_i="16068" txt_f="16073">et al</offsets></italic><offsets xml_i="21703" xml_f="22483" txt_i="16073" txt_f="16853">. in 2010 have concluded that dexmedetomidine (100 μg) when used as an additive to 40 ml of 0.5% levobupivacaine prolongs axillary brachial plexus block duration. They have shown that dexmedetomidine shortened the sensory block onset time (9.03 ± 1.15 min in dexmedetomidine group vs. 10.46 ± 1.30 min in control group), the motor block onset time (9.50 ± 1.04 min in dexmedetomidine group vs 11.10 ± 1.24 min in control group) and prolonged the duration of the sensory block (887 ± 66.23 min in dexmedetomidine group and 673 ± 73.77 min in control group), duration of the motor block (773 ± 67.62 min in dexmedetomidine group and 575 ± 65 min in control group) and postoperative analgesia (1008.69 ± 164.04 min in dexmedetomidine group and 887.14 ± 260.82 min in control group).[</offsets><xref rid="ref10" ref-type="bibr"><offsets xml_i="22517" xml_f="22519" txt_i="16853" txt_f="16855">10</offsets></xref><offsets xml_i="22526" xml_f="22537" txt_i="16855" txt_f="16866">] Esmaoglu </offsets><italic><offsets xml_i="22545" xml_f="22550" txt_i="16866" txt_f="16871">et al</offsets></italic><offsets xml_i="22559" xml_f="22866" txt_i="16871" txt_f="17178">. used nerve stimulation as the guidance method and 40 ml local anesthetic plus 100 mg dexmedetomidine was administered for axillary brachial plexus block. Nowadays, ultrasound guidance is described as the “golden standard” in peripheral regional anesthesia which enables reduction in local anesthetic dose.</offsets></p><p><offsets xml_i="22873" xml_f="22879" txt_i="17179" txt_f="17185">Swami </offsets><italic><offsets xml_i="22887" xml_f="22892" txt_i="17185" txt_f="17190">et al</offsets></italic><offsets xml_i="22901" xml_f="23135" txt_i="17190" txt_f="17424">. in 2012 concluded that dexmedetomidine (1 μg/kg) when added to local anesthetic (35cc, bupivacaine 0.25%) in supraclavicular brachial plexus block enhanced the duration of sensory and motor block and also the duration of analgesia.[</offsets><xref rid="ref11" ref-type="bibr"><offsets xml_i="23169" xml_f="23171" txt_i="17424" txt_f="17426">11</offsets></xref><offsets xml_i="23178" xml_f="23338" txt_i="17426" txt_f="17586">] The time for rescue analgesia was prolonged in patients receiving dexmedetomidine. It also enhanced the quality of block as compared with clonidine (1 μg/kg).</offsets></p><p><offsets xml_i="23345" xml_f="23351" txt_i="17587" txt_f="17593">Zhang </offsets><italic><offsets xml_i="23359" xml_f="23364" txt_i="17593" txt_f="17598">et al</offsets></italic><offsets xml_i="23373" xml_f="23592" txt_i="17598" txt_f="17817">. in 2014 also reported prolonged sensory and motor blockade duration in patients who received dexmedetomidine (50 μg) in 40 ml of 0.33% ropivacaine when compared to control group for axillary brachial plexus blockade.[</offsets><xref rid="ref6" ref-type="bibr"><offsets xml_i="23625" xml_f="23626" txt_i="17817" txt_f="17818">6</offsets></xref><offsets xml_i="23633" xml_f="23775" txt_i="17818" txt_f="17960">] However, dexmedetomidine was also associated with an increased incidence of side effects such as bradycardia, hypertension, and hypotension.</offsets></p><p><offsets xml_i="23782" xml_f="23820" txt_i="17961" txt_f="17999">In the accordance with study by Swami </offsets><italic><offsets xml_i="23828" xml_f="23833" txt_i="17999" txt_f="18004">et al</offsets></italic><offsets xml_i="23842" xml_f="23844" txt_i="18004" txt_f="18006">.[</offsets><xref rid="ref11" ref-type="bibr"><offsets xml_i="23878" xml_f="23880" txt_i="18006" txt_f="18008">11</offsets></xref><offsets xml_i="23887" xml_f="23902" txt_i="18008" txt_f="18023">] and Esmaoglu </offsets><italic><offsets xml_i="23910" xml_f="23915" txt_i="18023" txt_f="18028">et al</offsets></italic><offsets xml_i="23924" xml_f="23926" txt_i="18028" txt_f="18030">.[</offsets><xref rid="ref10" ref-type="bibr"><offsets xml_i="23960" xml_f="23962" txt_i="18030" txt_f="18032">10</offsets></xref><offsets xml_i="23969" xml_f="24164" txt_i="18032" txt_f="18227">] in our study no significant serious side effects were reported in any group except for lower pulse rates and blood pressures observed in dexmedetomidine groups that were managed conservatively.</offsets></p><p><offsets xml_i="24171" xml_f="24356" txt_i="18228" txt_f="18413">In a study on sciatic nerve block in rats, addition of dexmedetomidine to ropivacaine resulted in increased duration of sensory and motor block and showed no evidence of neurotoxicity.[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="24389" xml_f="24390" txt_i="18413" txt_f="18414">5</offsets></xref><offsets xml_i="24397" xml_f="24546" txt_i="18414" txt_f="18563">] In addition, use of dexmedetomidine decreases inflammation around peripheral nerves, thereby decreasing the potential for peripheral nerve injury.[</offsets><xref rid="ref12" ref-type="bibr"><offsets xml_i="24580" xml_f="24582" txt_i="18563" txt_f="18565">12</offsets></xref><offsets xml_i="24589" xml_f="24809" txt_i="18565" txt_f="18785">] Thus, use of dexmedetomidine is safe in peripheral nerve blocks. Supporting the animal study data no neurological deficit was observed in any of our patients. No neurological deficit was reported in the study by Swami </offsets><italic><offsets xml_i="24817" xml_f="24822" txt_i="18785" txt_f="18790">et al</offsets></italic><offsets xml_i="24831" xml_f="24833" txt_i="18790" txt_f="18792">.[</offsets><xref rid="ref11" ref-type="bibr"><offsets xml_i="24867" xml_f="24869" txt_i="18792" txt_f="18794">11</offsets></xref><offsets xml_i="24876" xml_f="24891" txt_i="18794" txt_f="18809">] and Esmaoglu </offsets><italic><offsets xml_i="24899" xml_f="24904" txt_i="18809" txt_f="18814">et al</offsets></italic><offsets xml_i="24913" xml_f="24915" txt_i="18814" txt_f="18816">.[</offsets><xref rid="ref10" ref-type="bibr"><offsets xml_i="24949" xml_f="24951" txt_i="18816" txt_f="18818">10</offsets></xref><offsets xml_i="24958" xml_f="24965" txt_i="18818" txt_f="18825">] also.</offsets></p><p><offsets xml_i="24972" xml_f="25833" txt_i="18826" txt_f="19687">Besides studying the effect of adding dexmedetomidine to ropivacaine when administered through brachial plexus blockade, we also studied the effect of intravenous supplementation of dexmedetomidine (50 μg) in patients who received 30 ml ropivacaine 0.5% in ultrasound-guided supraclavicular brachial plexus block and found that it also resulted in quick onset of sensory and motor block, prolonged duration of both sensory and motor block, delayed time to first request for analgesia supplementation, and significantly decreased 24 h analgesic consumption and a good quality of analgesia when compared with control group (ropivacaine 0.5% alone in block). However, the sensory and motor block onset was found to be significantly quicker when dexmedetomidine was given in block when compared to when it was administered intravenously suggesting the presence of α</offsets><sub><offsets xml_i="25838" xml_f="25839" txt_i="19687" txt_f="19688">2</offsets></sub><offsets xml_i="25845" xml_f="26232" txt_i="19688" txt_f="20075"> -ARs in brachial plexus and hence a faster local action. The duration of sensory and motor block was also significantly more prolonged when dexmedetomidine was given in block than when it was administered intravenously. However, the increased duration of analgesia and decreased total analgesic consumption in 24 h postoperative period was comparable in both the dexmedetomidine groups.</offsets></p><p><offsets xml_i="26239" xml_f="26248" txt_i="20076" txt_f="20085">Marhofer </offsets><italic><offsets xml_i="26256" xml_f="26261" txt_i="20085" txt_f="20090">et al</offsets></italic><offsets xml_i="26270" xml_f="26272" txt_i="20090" txt_f="20092">.[</offsets><xref rid="ref7" ref-type="bibr"><offsets xml_i="26305" xml_f="26306" txt_i="20092" txt_f="20093">7</offsets></xref><offsets xml_i="26313" xml_f="26583" txt_i="20093" txt_f="20363">] also reported a profound prolongation of ulnar nerve block (UNB) of 60% with perineural dexmedetomidine when added to 0.75% ropivacaine. Whereas, systemic administration of 20 mg dexmedetomidine resulted in a prolongation of only 10% during UNB with 0.75% ropivacaine.</offsets></p><p><offsets xml_i="26590" xml_f="26633" txt_i="20364" txt_f="20407">The mechanism of the analgesic actions of α</offsets><sub><offsets xml_i="26638" xml_f="26639" txt_i="20407" txt_f="20408">2</offsets></sub><offsets xml_i="26645" xml_f="26831" txt_i="20408" txt_f="20594"> agonists has not been fully elucidated and is probably multifactorial. A number of supraspinal and spinal sites modulate the transmission of nociceptive signals in the CNS. Peripheral α</offsets><sub><offsets xml_i="26836" xml_f="26837" txt_i="20594" txt_f="20595">2</offsets></sub><offsets xml_i="26843" xml_f="26896" txt_i="20595" txt_f="20648"> adrenoceptors may also mediate the antinociception.[</offsets><xref rid="ref15" ref-type="bibr"><offsets xml_i="26930" xml_f="26932" txt_i="20648" txt_f="20650">15</offsets></xref><offsets xml_i="26939" xml_f="26942" txt_i="20650" txt_f="20653">] α</offsets><sub><offsets xml_i="26947" xml_f="26948" txt_i="20653" txt_f="20654">2</offsets></sub><offsets xml_i="26954" xml_f="27090" txt_i="20654" txt_f="20790"> blockers by acting at any of these sites reduce nociceptive transmission, leading to analgesia. The activation of inwardly rectifying G</offsets><sub><offsets xml_i="27095" xml_f="27096" txt_i="20790" txt_f="20791">1</offsets></sub><offsets xml_i="27102" xml_f="27320" txt_i="20791" txt_f="21009"> -protein-gated potassium channels resulting in membrane hyperpolarization and decreasing the firing rate of excitable cells in the CNS is considered to be a significant mechanism of the inhibitory neuronal action of α</offsets><sub><offsets xml_i="27325" xml_f="27326" txt_i="21009" txt_f="21010">2</offsets></sub><offsets xml_i="27332" xml_f="27357" txt_i="21010" txt_f="21035"> -adrenoceptor agonists.[</offsets><xref rid="ref16" ref-type="bibr"><offsets xml_i="27391" xml_f="27393" txt_i="21035" txt_f="21037">16</offsets></xref><offsets xml_i="27400" xml_f="27539" txt_i="21037" txt_f="21176">] Reduction of calcium conductance into cells, thus inhibiting neurotransmitter release is other prominent physiologic action ascribed to α</offsets><sub><offsets xml_i="27544" xml_f="27545" txt_i="21176" txt_f="21177">2</offsets></sub><offsets xml_i="27551" xml_f="27747" txt_i="21177" txt_f="21373"> adrenoceptors. This effect involves direct regulation of entry of calcium through N-type voltage-gated calcium channels and is independent of cAMP and protein phosphorylation and is mediated by G</offsets><sub><offsets xml_i="27752" xml_f="27753" txt_i="21373" txt_f="21374">0</offsets></sub><offsets xml_i="27759" xml_f="27949" txt_i="21374" txt_f="21564"> proteins. These mechanisms represent 2 very different ways of effecting analgesia, that is, the nerve is prevented from firing, and it also prevents propagation of signals to the neighbors.</offsets></p><p><offsets xml_i="27956" xml_f="28623" txt_i="21565" txt_f="22232">Hence, we hypothesize that it is mainly the direct peripheral action of dexmedetomidine on nerves in block, which is responsible for these improvements rather than due to central action of dexmedetomidine after absorption through block site into systemic circulation resulting in its systemic effects. However, the central effects of dexmedetomidine also seems to play some role in prolongation of sensory and motor block duration, as 50 μg of dexmedetomidine intravenous infusion significantly prolonged brachial plexus block duration when compared to control group in our study. However, further detailed studies are warranted to investigate the mechanisms of how α</offsets><sub><offsets xml_i="28628" xml_f="28629" txt_i="22232" txt_f="22233">2</offsets></sub><offsets xml_i="28635" xml_f="28730" txt_i="22233" txt_f="22328"> agonists, and especially dexmedetomidine, prolong the action of LA in peripheral nerve blocks.</offsets></p></sec><sec id="sec1-5"><title><offsets xml_i="28764" xml_f="28788" txt_i="22330" txt_f="22354">LIMITATIONS OF THE STUDY</offsets></title><p><offsets xml_i="28799" xml_f="29031" txt_i="22355" txt_f="22587">The major limitation of this study was that we did not measure the levels of dexmedetomidine in the plasma that could have further supported the hypothesis that dexmedetomidine has a peripheral action rather than centrally mediated.</offsets></p></sec><sec sec-type="conclusion" id="sec1-6"><title><offsets xml_i="29087" xml_f="29097" txt_i="22589" txt_f="22599">CONCLUSION</offsets></title><p><offsets xml_i="29108" xml_f="29575" txt_i="22600" txt_f="23067">Thus, we conclude that in supraclavicular brachial plexus block addition of dexmedetomidine as adjuvant to 0.5% ropivacaine shortens the sensory and motor block onset time, prolongs both sensory and motor block duration. It also significantly delays the first demand for analgesia supplementation, decreases 24 h analgesic consumption and is not associated with any major side-effect. The action of dexmedetomidine is most probably peripheral than centrally mediated.</offsets></p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Halstead</surname><given-names>C</given-names></name></person-group><article-title>Great moments in the history of anaesthesiology</article-title><source>In: A Practice of Anesthesia</source><year>2003</year><edition>7th ed</edition><publisher-loc>London, UK</publisher-loc><publisher-name>Lioyd-Luke</publisher-name><fpage>5</fpage></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>DB</given-names></name><name><surname>McCartney</surname><given-names>CJ</given-names></name><name><surname>Chan</surname><given-names>VW</given-names></name></person-group><article-title>Novel analgesic adjuncts for brachial plexus block: a systematic review</article-title><source>Anesth Analg</source><year>2000</year><volume>90</volume><fpage>1122</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10781465</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutkowska</surname><given-names>K</given-names></name><name><surname>Knapik</surname><given-names>P</given-names></name><name><surname>Misiolek</surname><given-names>H</given-names></name></person-group><article-title>The effect of dexmedetomidine sedation on brachial plexus block in patients with end-stage renal disease</article-title><source>Eur J Anaesthesiol</source><year>2009</year><volume>26</volume><fpage>851</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">19550340</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brummett</surname><given-names>CM</given-names></name><name><surname>Norat</surname><given-names>MA</given-names></name><name><surname>Palmisano</surname><given-names>JM</given-names></name><name><surname>Lydic</surname><given-names>R</given-names></name></person-group><article-title>Perineural administration of dexmedetomidine in combination with bupivacaine enhances sensory and motor blockade in sciatic nerve block without inducing neurotoxicity in rat</article-title><source>Anesthesiology</source><year>2008</year><volume>109</volume><fpage>502</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">18719449</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brummett</surname><given-names>CM</given-names></name><name><surname>Padda</surname><given-names>AK</given-names></name><name><surname>Amodeo</surname><given-names>FS</given-names></name><name><surname>Welch</surname><given-names>KB</given-names></name><name><surname>Lydic</surname><given-names>R</given-names></name></person-group><article-title>Perineural dexmedetomidine added to ropivacaine causes a dose-dependent increase in the duration of thermal antinociception in sciatic nerve block in rat</article-title><source>Anesthesiology</source><year>2009</year><volume>111</volume><fpage>1111</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19858875</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>CS</given-names></name><name><surname>Shi</surname><given-names>JH</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>SJ</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Perineural administration of dexmedetomidine in combination with ropivacaine prolongs axillary brachial plexus block</article-title><source>Int J Clin Exp Med</source><year>2014</year><volume>7</volume><fpage>680</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">24753763</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marhofer</surname><given-names>D</given-names></name><name><surname>Kettner</surname><given-names>SC</given-names></name><name><surname>Marhofer</surname><given-names>P</given-names></name><name><surname>Pils</surname><given-names>S</given-names></name><name><surname>Weber</surname><given-names>M</given-names></name><name><surname>Zeitlinger</surname><given-names>M</given-names></name></person-group><article-title>Dexmedetomidine as an adjuvant to ropivacaine prolongs peripheral nerve block: A volunteer study</article-title><source>Br J Anaesth</source><year>2013</year><volume>110</volume><fpage>438</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">23161360</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanazi</surname><given-names>GE</given-names></name><name><surname>Aouad</surname><given-names>MT</given-names></name><name><surname>Jabbour-Khoury</surname><given-names>SI</given-names></name><name><surname>Al Jazzar</surname><given-names>MD</given-names></name><name><surname>Alameddine</surname><given-names>MM</given-names></name><name><surname>Al-Yaman</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Effect of low-dose dexmedetomidine or clonidine on the characteristics of bupivacaine spinal block</article-title><source>Acta Anaesthesiol Scand</source><year>2006</year><volume>50</volume><fpage>222</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16430546</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>S</given-names></name><name><surname>Aggarwal</surname><given-names>R</given-names></name><name><surname>Gupta</surname><given-names>P</given-names></name></person-group><article-title>Dexmedetomidine prolongs the effect of bupivacaine in supraclavicular brachial plexus block</article-title><source>J Anaesthesiol Clin Pharmacol</source><year>2014</year><volume>30</volume><fpage>36</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">24574591</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esmaoglu</surname><given-names>A</given-names></name><name><surname>Yegenoglu</surname><given-names>F</given-names></name><name><surname>Akin</surname><given-names>A</given-names></name><name><surname>Turk</surname><given-names>CY</given-names></name></person-group><article-title>Dexmedetomidine added to levobupivacaine prolongs axillary brachial plexus block</article-title><source>Anesth Analg</source><year>2010</year><volume>111</volume><fpage>1548</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">20889939</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swami</surname><given-names>SS</given-names></name><name><surname>Keniya</surname><given-names>VM</given-names></name><name><surname>Ladi</surname><given-names>SD</given-names></name><name><surname>Rao</surname><given-names>R</given-names></name></person-group><article-title>Comparison of dexmedetomidine and clonidine (a2 agonist drugs) as an adjuvant to local Anesthesia in supraclavicular brachial plexus block: A randomised double-blind prospective study</article-title><source>Indian J Anaesth</source><year>2012</year><volume>56</volume><fpage>243</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22923822</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brummett</surname><given-names>CM</given-names></name><name><surname>Amodeo</surname><given-names>FS</given-names></name><name><surname>Janda</surname><given-names>AM</given-names></name><name><surname>Padda</surname><given-names>AK</given-names></name><name><surname>Lydic</surname><given-names>R</given-names></name></person-group><article-title>Perineural dexmedetomidine provides an increased duration of analgesia to a thermal stimulus when compared with a systemic control in a rat sciatic nerve block</article-title><source>Reg Anesth Pain Med</source><year>2010</year><volume>35</volume><fpage>427</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">20814283</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>SM</given-names></name><name><surname>Greengrass</surname><given-names>RA</given-names></name><name><surname>Steele</surname><given-names>SM</given-names></name><name><surname>D’Ercole</surname><given-names>FJ</given-names></name><name><surname>Speer</surname><given-names>KP</given-names></name><name><surname>Gleason</surname><given-names>DH</given-names></name><etal></etal></person-group><article-title>A comparison of 0.5% bupivacaine, 0.5% ropivacaine, and 0.75% ropivacaine for interscalene brachial plexus block</article-title><source>Anesth Analg</source><year>1998</year><volume>87</volume><fpage>1316</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9842819</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hickey</surname><given-names>R</given-names></name><name><surname>Rowley</surname><given-names>CL</given-names></name><name><surname>Candido</surname><given-names>KD</given-names></name><name><surname>Hoffman</surname><given-names>J</given-names></name><name><surname>Ramamurthy</surname><given-names>S</given-names></name><name><surname>Winnie</surname><given-names>AP</given-names></name></person-group><article-title>A comparative study of 0.25% ropivacaine and 0.25% bupivacaine for brachial plexus block</article-title><source>Anesth Analg</source><year>1992</year><volume>75</volume><fpage>602</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">1530173</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Ferreira</surname><given-names>SH</given-names></name></person-group><article-title>Peripheral analgesic action of clonidine: Mediation by release of endogenous enkephalin-like substances</article-title><source>Eur J Pharmacol</source><year>1988</year><volume>146</volume><fpage>223</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">3163552</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birnbaumer</surname><given-names>L</given-names></name><name><surname>Abramowitz</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>AM</given-names></name></person-group><article-title>Receptor-effector coupling by G proteins</article-title><source>Biochim Biophys Acta</source><year>1990</year><volume>1031</volume><fpage>163</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">2160274</pub-id></element-citation></ref></ref-list></back></article>